Skip to main content

Progressive Supranuclear Palsy

8
Pipeline Programs
16
Companies
15
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
8
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 16 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Gemvax & KAEL
Gemvax & KAELKorea - Seongnam
2 programs
2
GV1001 PlaceboPhase 21 trial
GV1001 PlaceboPhase 21 trial
Active Trials
NCT06235775Completed67Est. Sep 2025
NCT05819658Completed78Est. Oct 2024
Alzprotect
AlzprotectFrance - Loos
1 program
1
AZP2006Phase 21 trial
Active Trials
NCT04008355Completed36Est. Sep 2024
Ferrer
FerrerSpain - Barcelona
1 program
1
FNP-223Phase 21 trial
Active Trials
NCT06355531Active Not Recruiting241Est. Nov 2026
EmeraMed
EmeraMedIreland - Dublin
1 program
1
NBMIPhase 21 trial
Active Trials
NCT04184063Completed20Est. Jun 2021
Elysium Therapeutics
1 program
1
Nicotinamide RibosidePhase 2
Nevro
NevroCA - Redwood City
1 program
1
Nicotinamide RibosidePhase 21 trial
Active Trials
NCT06162013Recruiting330Est. Dec 2028
Transposon Therapeutics
1 program
1
TPN-101, 100 mg/dayPhase 21 trial
Active Trials
NCT04993768Completed42Est. Mar 2024
UCB Pharma
UCB PharmaBelgium - Brussels
3 programs
Verily Study WatchN/A1 trial
UCB0107PHASE_11 trial
bepranemabPHASE_1Monoclonal Antibody1 trial
Active Trials
NCT05501431Completed100Est. Sep 2024
NCT04658199Active Not Recruiting19Est. Dec 2027
NCT04185415Completed25Est. Nov 2021
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Postural Instability in Progressive Supranuclear PalsyN/A1 trial
Active Trials
NCT01563276Completed36Est. May 2013
Verily Life Sciences
1 program
Verily Study WatchN/A
Biogen
BiogenCAMBRIDGE, MA
1 program
BIIB092PHASE_11 trial
Active Trials
NCT02460094Completed48Est. Oct 2016
C2N Diagnostics
C2N DiagnosticsMO - St. Louis
1 program
Single dose C2N-8E12PHASE_11 trial
Active Trials
NCT02494024Completed32Est. Aug 2016
Life Molecular Imaging
Life Molecular ImagingGermany - Berlin
1 program
[18F]-PI2620PHASE_11 trial
Active Trials
NCT05187546Completed15Est. Mar 2024
Teva
TevaIsrael - Petach Tikva
1 program
RasagilinePHASE_31 trial
Active Trials
NCT01187888Terminated44Est. Jun 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
TevaRasagiline
FerrerFNP-223
NevroNicotinamide Riboside
Gemvax & KAELGV1001 Placebo
Gemvax & KAELGV1001 Placebo
Transposon TherapeuticsTPN-101, 100 mg/day
AlzprotectAZP2006
EmeraMedNBMI
Life Molecular Imaging[18F]-PI2620
UCB PharmaUCB0107
UCB Pharmabepranemab
BiogenBIIB092
C2N DiagnosticsSingle dose C2N-8E12
UCB PharmaVerily Study Watch
Oregon TherapeuticsPostural Instability in Progressive Supranuclear Palsy

Clinical Trials (15)

Total enrollment: 1,133 patients across 15 trials

NCT01187888TevaRasagiline

Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy

Start: Jan 2010Est. completion: Jun 201244 patients
Phase 3Terminated
NCT06355531FerrerFNP-223

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Start: Jul 2024Est. completion: Nov 2026241 patients
Phase 2Active Not Recruiting
NCT06162013NevroNicotinamide Riboside

The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism

Start: Mar 2024Est. completion: Dec 2028330 patients
Phase 2Recruiting
NCT06235775Gemvax & KAELGV1001 Placebo

Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

Start: Dec 2023Est. completion: Sep 202567 patients
Phase 2Completed
NCT05819658Gemvax & KAELGV1001 Placebo

GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)

Start: Jun 2023Est. completion: Oct 202478 patients
Phase 2Completed
NCT04993768Transposon TherapeuticsTPN-101, 100 mg/day

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Start: Dec 2021Est. completion: Mar 202442 patients
Phase 2Completed
NCT04008355AlzprotectAZP2006

A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP

Start: Jun 2020Est. completion: Sep 202436 patients
Phase 2Completed
NCT04184063EmeraMedNBMI

Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)

Start: Sep 2019Est. completion: Jun 202120 patients
Phase 2Completed
NCT05187546Life Molecular Imaging[18F]-PI2620

Test-retest Study With [18F]PI-2620 in PSP-RS and NDC

Start: Mar 2022Est. completion: Mar 202415 patients
Phase 1Completed
NCT04658199UCB PharmaUCB0107

A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

Start: Nov 2020Est. completion: Dec 202719 patients
Phase 1Active Not Recruiting
NCT04185415UCB Pharmabepranemab

A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)

Start: Dec 2019Est. completion: Nov 202125 patients
Phase 1Completed
NCT02460094BiogenBIIB092

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

Start: Oct 2015Est. completion: Oct 201648 patients
Phase 1Completed
NCT02494024C2N DiagnosticsSingle dose C2N-8E12

Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

Start: Jul 2015Est. completion: Aug 201632 patients
Phase 1Completed
NCT05501431UCB PharmaVerily Study Watch

Personalized Parkinson Project PSP Cohort

Start: May 2021Est. completion: Sep 2024100 patients
N/ACompleted
NCT01563276Oregon TherapeuticsPostural Instability in Progressive Supranuclear Palsy

Postural Instability in Progressive Supranuclear Palsy

Start: Dec 2011Est. completion: May 201336 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,133 patients
16 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.